tradingkey.logo

RxSight expects preliminary Q2 revenue down 4%

ReutersJul 8, 2025 8:17 PM


Overview

  • RxSight's preliminary Q2 2025 revenue expected to be down 4% yr/yr, missing analyst expectations, per LSEG data

  • Company revises 2025 revenue guidance downward, gross margin guidance upward

  • Sale of Light Delivery Devices decreased 45% compared to Q1 2025


Outlook

  • RxSight revises 2025 revenue guidance to $120 mln-$130 mln, down from $160 mln-$175 mln.

  • Company increases 2025 gross margin guidance to 72%-74%, up from 71%-73%.

  • RxSight sees 2025 operating expense guidance between $145 mln-$155 mln.


Result Drivers

  • REVENUE DECLINE - Q2 2025 revenue expected to fall 4% year-over-year and 11% from Q1 2025, missing analyst expectations, on decreased sales of Light Delivery Devices

  • LDD SALES DROP - Sales of Light Delivery Devices decreased 45% compared to Q1 2025 and 49% compared to Q2 2024

  • LAL SALES GROWTH - Despite overall revenue decline, Light Adjustable Lenses sales increased 13% compared to Q2 2024


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$33.60 mln

$39.80 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Rxsight Inc is $21.00, about 40.8% above its July 7 closing price of $12.43

Press Release: ID:nGNX2LHj70

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI